Is Morganella Bacteria Common for UTI?
No, Morganella morganii is NOT a common cause of urinary tract infections—it is an uncommon opportunistic pathogen that primarily affects specific high-risk populations.
Epidemiology and Clinical Context
Morganella morganii is a Gram-negative bacillus that belongs to the Enterobacteriaceae family and is part of normal gastrointestinal flora. While it can cause UTIs, it does not appear among the commonly listed uropathogens in current guidelines.
According to the 2024 European Association of Urology guidelines, the most common species found in complicated UTI cultures are E. coli, Proteus spp., Klebsiella spp., Pseudomonas spp., Serratia spp., and Enterococcus spp. 1. Notably, Morganella is conspicuously absent from this list of common pathogens.
When to Suspect Morganella morganii
Despite being uncommon, M. morganii should be considered in specific clinical scenarios:
High-Risk Populations:
- Immunocompromised patients (chemotherapy, immunosuppressant therapy) 2
- Patients with underlying urological abnormalities, particularly:
- Catheterized patients (nosocomial/healthcare-associated infections) 4, 3
- Pediatric patients with nephrotic syndrome (72.7% in one case series) 2
- Elderly patients with recurrent UTIs 5
Clinical Presentation:
M. morganii UTIs often present as lower urinary tract infections with relatively mild laboratory findings—normal or slightly elevated leukocyte counts and procalcitonin levels, with normal C-reactive protein 2. This contrasts with typical bacterial UTIs that may show more pronounced inflammatory markers.
Antibiotic Susceptibility Profile
Critical resistance pattern: M. morganii exhibits intrinsic resistance to certain antibiotics commonly used for empiric UTI treatment:
- Uniformly resistant to: Amoxicillin-clavulanate and nitrofurantoin 3
- Uniformly sensitive to: Amikacin, cefepime, piperacillin-tazobactam, aztreonam, carbapenems (ertapenem, meropenem), ceftazidime, and cefoperazone/sulbactam 2, 3
This resistance profile is important because amoxicillin-clavulanate and nitrofurantoin are frequently used for uncomplicated UTIs, making empiric therapy potentially ineffective if M. morganii is the causative organism.
Clinical Implications
When M. morganii is Isolated:
- Review patient risk factors for opportunistic infection (immunosuppression, urological abnormalities, catheter use)
- Treat according to complicated UTI protocols per guidelines 1
- Use culture-directed therapy with third-generation cephalosporins or carbapenems 2, 6
- Consider source control if catheter-associated 1
Mortality Considerations:
While uncommon, M. morganii infections can be serious. Bloodstream infections carry a 41% in-hospital mortality rate, with increased risk in ICU patients, those over 65 years, and patients with co-infections 7. This underscores the importance of appropriate antibiotic selection when this organism is identified.
Common Pitfall
Do not dismiss M. morganii as a contaminant in patients with the risk factors listed above, particularly those with urological abnormalities or immunosuppression. While rare, it represents a true pathogen in these populations and requires targeted therapy based on susceptibility testing 2, 4, 3.